Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The solvency position, as indicated by the presented ratios, exhibits both stability and fluctuation over the observed period. Generally, the company maintained a moderate level of debt relative to its equity, capital, and assets for much of the period, but recent quarters show a shift towards increased leverage. A notable decline in interest coverage occurred in the latter part of the period, raising concerns about the ability to comfortably meet interest obligations.
- Debt to Equity
- The debt to equity ratio generally decreased from 1.32 in March 2022 to 1.10 in December 2025. However, this trend was interrupted by an increase to 1.44 in March 2024, followed by a decline to 1.30 in March 2025 and 1.27 in June 2025. This suggests a recent increase in reliance on equity financing or a reduction in debt, though the initial spike warrants further investigation.
- Debt to Capital
- The debt to capital ratio demonstrated a consistent, albeit gradual, decline from 0.57 in March 2022 to 0.52 in December 2025. This indicates a decreasing proportion of debt financing relative to the company’s total capital structure. The decrease is relatively small, suggesting a measured approach to capital structure management.
- Debt to Assets
- Similar to the debt to capital ratio, the debt to assets ratio showed a steady decrease from 0.42 in March 2022 to 0.42 in December 2025. A slight increase to 0.45 was observed in March 2024, but it reverted to 0.43 and 0.42 in subsequent quarters. This suggests a stable relationship between debt and the company’s asset base.
- Financial Leverage
- Financial leverage, as measured by the ratio, generally decreased from 3.17 in March 2022 to 2.60 in December 2025. However, a significant increase to 3.21 was recorded in March 2024, before declining again. This fluctuation mirrors the trend observed in the debt to equity ratio, indicating a period of increased leverage followed by a reduction.
- Interest Coverage
- The interest coverage ratio exhibited a substantial decline in the latter half of the period. While relatively strong at 6.97 in March 2022, it decreased to 8.27 in December 2022, then to a low of 1.18 in September 2024. A recovery was observed in subsequent quarters, reaching 10.57 in December 2025. This significant drop and subsequent recovery suggest potential changes in earnings or interest expense that require further scrutiny. The low values in late 2024 raise concerns about the company’s ability to comfortably cover its interest obligations.
In summary, the company demonstrated a generally stable solvency position for the majority of the period, with a slight trend towards reduced leverage. However, the recent increase in debt ratios and the significant decline in interest coverage warrant close monitoring to assess the sustainability of the company’s financial health.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current portion of long-term debt, net | |||||||||||||||||||||
| Long-term debt, net, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total Gilead stockholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Total Gilead stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio for the analyzed period demonstrates fluctuations, generally exhibiting a decreasing trend over the observed timeframe, with a recent increase. Initially, the ratio decreased from 1.32 in March 2022 to 1.09 in December 2022. A subsequent increase to 1.44 was observed in March 2024, followed by a decline to 1.10 by December 2025.
- Initial Decreasing Trend (Mar 31, 2022 – Dec 31, 2022)
- From the first quarter of 2022 through the end of the year, the debt to equity ratio consistently decreased. This suggests a strengthening of the equity position relative to debt, or a reduction in debt levels, or a combination of both. The decrease, while not dramatic, indicates improving solvency during this period.
- Fluctuation and Increase (Jan 1, 2023 – Mar 31, 2024)
- The ratio remained relatively stable between 1.12 and 1.20 for the first three quarters of 2023. However, a notable increase to 1.44 occurred in March 2024. This suggests a significant increase in debt, a decrease in equity, or a combination of both, potentially indicating increased financial leverage or a revaluation of equity.
- Subsequent Decline (Apr 1, 2024 – Dec 31, 2025)
- Following the peak in March 2024, the debt to equity ratio experienced a decline, reaching 1.10 by December 2025. This indicates a subsequent effort to reduce debt or bolster equity, partially offsetting the increase observed earlier in the year. The ratio’s movement suggests a dynamic capital structure management strategy.
- Total Debt and Equity Movements
- Total debt remained relatively consistent between US$24,936 million and US$26,230 million throughout the period. Total stockholders’ equity experienced more significant fluctuations, decreasing from US$22,833 million in December 2022 to US$17,539 million in March 2024, before recovering to US$22,703 million by December 2025. These movements in equity appear to be a primary driver of the observed changes in the debt to equity ratio.
Overall, the debt to equity ratio indicates a period of improving solvency followed by a temporary increase in leverage, and then a subsequent recovery. The fluctuations suggest active management of the capital structure, with equity levels playing a significant role in the ratio’s movements.
Debt to Capital
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current portion of long-term debt, net | |||||||||||||||||||||
| Long-term debt, net, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total Gilead stockholders’ equity | |||||||||||||||||||||
| Total capital | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio for the analyzed period demonstrates a generally decreasing trend with some fluctuations. Initially, the ratio exhibited a slight decline from 0.57 in March 2022 to 0.54 by September 2022, remaining at that level through December 2022. A modest increase was then observed, reaching 0.55 in March 2023 and 0.56 in June 2023, before resuming a downward trajectory to 0.52 by December 2023.
A notable increase occurred in the first quarter of 2024, with the ratio rising to 0.59. This was followed by a decrease to 0.56 in June 2024. A further increase to 0.58 in September 2024 was observed, followed by a significant jump to 0.61 in December 2024. The ratio then decreased to 0.57 in March 2025, 0.56 in June 2025, and continued to decline to 0.54 in September 2025, concluding the period at 0.52 in December 2025.
- Overall Trend
- Despite interim increases, the overall trend indicates a reduction in the proportion of debt relative to total capital over the analyzed timeframe. The ratio decreased from 0.57 at the beginning of the period to 0.52 at the end.
- Fluctuations
- The ratio experienced periods of stability and fluctuation. The period between March 2022 and December 2022 showed relative stability. The increase in the ratio during the first quarter of 2024 and the end of 2024 represents a deviation from the overall downward trend, warranting further investigation into the underlying factors contributing to these changes.
- Recent Performance
- The most recent quarters show a consistent decline in the debt to capital ratio, from 0.57 in March 2025 to 0.52 in December 2025. This suggests a recent focus on reducing leverage or increasing capital.
The observed changes in the debt to capital ratio suggest shifts in the company’s capital structure. The fluctuations require further analysis to determine the specific drivers, such as changes in debt levels, equity issuance, or retained earnings.
Debt to Assets
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current portion of long-term debt, net | |||||||||||||||||||||
| Long-term debt, net, excluding current portion | |||||||||||||||||||||
| Total debt | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio for the analyzed period demonstrates a generally stable profile with some fluctuations. Initially, the ratio remained consistent at 0.42 for the first two quarters, before decreasing to 0.40 and remaining at that level for four consecutive quarters. A subsequent increase is observed, rising to 0.45 over the next three quarters, before decreasing slightly to 0.44 and then 0.43. The ratio then experiences another increase to 0.45, followed by a decrease to 0.42 by the end of the observed period.
- Overall Trend
- The overall trend indicates a moderate level of financial leverage. While the ratio fluctuates, it generally remains within a relatively narrow band between 0.40 and 0.45. This suggests a consistent, though not dramatically changing, reliance on debt financing relative to the company’s asset base.
- Initial Stability (Q1 2022 - Q4 2022)
- From March 31, 2022, through December 31, 2022, the debt-to-assets ratio exhibited stability. The initial value of 0.42 held for the first two quarters, followed by a decrease to 0.40, where it remained constant for the subsequent two quarters. This period suggests a consistent capital structure and potentially predictable debt management practices.
- Increase and Subsequent Fluctuation (Q1 2023 - Q4 2025)
- Beginning in March 2023, the ratio began to increase, reaching 0.45 by December 2023. This increase suggests a potential shift in financing strategy, possibly involving increased debt utilization. The ratio then fluctuated between 0.43 and 0.45 over the following quarters, indicating a period of adjustment or response to changing financial conditions. The final value of 0.42 suggests a slight reduction in leverage at the end of the analyzed period.
- Peak Ratio
- The highest recorded debt-to-assets ratio was 0.45, occurring three times throughout the period: December 31, 2023, September 30, 2024, and March 31, 2025. These instances represent the periods of highest relative debt financing.
- Lowest Ratio
- The lowest ratio observed was 0.40, maintained for four consecutive quarters from September 30, 2022, to June 30, 2023. This represents the period of lowest relative debt financing during the analyzed timeframe.
Financial Leverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Total Gilead stockholders’ equity | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Financial leverage, as indicated by the ratio presented, demonstrates a generally decreasing trend over the observed period, with some fluctuations. Initially, the ratio stood at 3.17 in March 2022 and experienced a gradual decline to 2.60 by December 2025. However, this decline was not linear, with periods of stability and even slight increases.
- Overall Trend
- The overarching trend reveals a reduction in financial leverage. This suggests the company is becoming less reliant on debt financing relative to its equity base. The decrease from 3.17 to 2.60 indicates a strengthening of the company’s financial position from a leverage perspective.
- Initial Decline (Mar 2022 – Sep 2022)
- From March 2022 to September 2022, the ratio decreased from 3.17 to 2.97. This initial decline suggests early efforts to reduce leverage, potentially through debt repayment or equity increases.
- Stabilization and Subsequent Decrease (Sep 2022 – Dec 2022)
- The ratio remained relatively stable between September 2022 and December 2022, fluctuating between 2.97 and 2.72. This period indicates a pause in the leverage reduction, potentially due to investment activities or other financial commitments.
- Increase and Subsequent Decline (Mar 2023 – Jun 2024)
- The ratio experienced a slight increase to 3.21 in March 2023 before resuming its downward trajectory. This temporary increase could be attributed to new debt issuance or a decrease in equity. The subsequent decline to 2.93 by June 2024 suggests a renewed focus on reducing leverage.
- Recent Trend (Jun 2024 – Dec 2025)
- From June 2024 to December 2025, the ratio continued its decline, moving from 2.93 to 2.60. This recent trend reinforces the overall pattern of decreasing financial leverage and suggests consistent efforts to improve the company’s capital structure.
The observed changes in financial leverage suggest a deliberate strategy to manage debt levels. The consistent downward trend, despite some short-term fluctuations, indicates a strengthening financial foundation and reduced risk associated with high debt obligations.
Interest Coverage
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) attributable to Gilead | |||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | |||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Interest coverage
= (EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025
+ EBITQ1 2025)
÷ (Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025
+ Interest expenseQ1 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage ratio exhibits considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates relative stability, followed by a period of significant decline and subsequent recovery.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The interest coverage ratio begins at 6.97 and fluctuates between 6.73 and 7.22. This indicates a consistently healthy ability to meet interest obligations with earnings before interest and tax. The variation within this period is moderate.
- Improvement (Mar 31, 2023 – Sep 30, 2023)
- A clear upward trend is observed from March 31, 2023, peaking at 10.71 on September 30, 2023. This suggests a strengthening of the company’s capacity to cover its interest expense, likely driven by increased earnings. The ratio consistently remains above 8.80 during this timeframe.
- Significant Decline (Dec 31, 2023 – Sep 30, 2024)
- A substantial decrease in the interest coverage ratio is evident, falling to a low of 1.18 on June 30, 2024. This decline is particularly pronounced, indicating a diminished ability to comfortably cover interest payments. The ratio remains below 2.58 throughout this period. This is likely attributable to a significant decrease in EBIT, as observed in the corresponding period.
- Recovery and Stabilization (Mar 31, 2025 – Dec 31, 2025)
- The ratio demonstrates a recovery, increasing to 10.57 by December 31, 2025. This suggests a restoration of earnings relative to interest expense. The ratio stabilizes above 7.94 during this period, indicating a return to a more secure position regarding interest coverage.
Overall, the interest coverage ratio demonstrates a cyclical pattern. While initially strong, a period of significant vulnerability emerges before a subsequent recovery. The most recent values suggest a return to a more favorable position, but the volatility observed throughout the period warrants continued monitoring.